<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Neuroscience</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F2B9F616-978F-43B8-ACCA-1F4A152FDD1C"><gtr:id>F2B9F616-978F-43B8-ACCA-1F4A152FDD1C</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Charles John</gtr:otherNames><gtr:surname>Miller</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62211B96-56AF-4672-8BA7-754E3F0AC07B"><gtr:id>62211B96-56AF-4672-8BA7-754E3F0AC07B</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501573"><gtr:id>F348B669-CC7A-44CF-BD31-DB61751D0832</gtr:id><gtr:title>Axonal transport, protein trafficking and neurological disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501573</gtr:grantReference><gtr:abstractText>There are currently no effective treatments for motor neuron disease/amyotrophic lateral sclerosis. Indeed, the mechanisms by which motor neurons die in ALS are not even properly understood. However, one of the earliest defects seen in models of the disease is disruption to movement of proteins through the cell by a process termed ?axonal transport?. Defective axonal transport is also seen in several other neurodegenerative diseases. This programme of studies is therefore to gain insight into the mechanisms by which axonal transport is damaged in ALS. We will disseminate our findings to the public in a variety of ways. Firstly, both Chris Miller and Chris Shaw regularly speak to lay audiences of patients and carers on their research at Motor Neurone Disease Association meetings. Chris Shaw has also communicated research findings and strategies on ALS to the public via radio and television broadcasts. In addition, the IOP hosts Open Days (which have been funded by the MRC) in which members of the public, through a series of talks and hands-on research presentations, are exposed to the wide range of neurodegenerative diseases-related research projects that are currently underway in the IOP. Finally, our findings are listed on the IOP WEB pages and receive exposure through the IOP press office.</gtr:abstractText><gtr:technicalSummary>The hypothesis that underlies this proposal is that defects in axonal transport and protein trafficking are part of the pathogenic process in three familial forms of amyotrophic lateral sclerosis (ALS). These familial forms are those caused by mutations in the genes encoding copper/zinc superoxide dismutase-1 (SOD1), ALS2/Alsin and vesicle-associated membrane protein-associated protein-B (VAPB). The aim of the project is to understand how these different genetic insults induce defects in neuronal protein transport. The primary objectives are:-
1) To identify p38 stress-activated kinase phosphorylation sites in neurofilament proteins and to determine how this influences axonal transport of neurofilaments. p38 is activated in ALS, phosphorylates neurofilaments which in turn is known to be a regulator of neurofilament transport. This will be achieved by sequencing neurofilament proteins isolated from neuronal cell bodies in which we have activated p38 by transfection of dominantly-active MKK3. MKK3 is a direct upstream activator of p38. Identified sites will then be mutated to preclude or to mimic permanent phosphorylation and the transport properties of these mutants analysed by monitoring movement of green fluorescent protein (GFP)-tagged variants in transfected cultured neurons.
2) To determine whether ALS mutant SOD1 induces changes in phosphorylation of kinesin and dynein family proteins. These are phosphoproteins and there is emerging evidence that they may be substrates for p38. This will involve proteomic analyses of motor proteins isolated from cells and tissues expressing wild-type or mutant SOD1. 
3) To determine how loss of ALS2 influences both fast and slow axonal transport by monitoring movement of GFP-tagged cargoes in living neurons derived from wild-type and ALS2 knockout mice.
4) To gain insight into the mechanisms by which ALS2 may signal to regulate axonal transport and how phosphorylation of ALS2 influences any such signalling.
5) To characterise new transgenic mouse models expressing ALS mutant VAPB that we have recently generated. 
6) To determine whether ALS mutant VAPB damages axonal transport and if so, to gain insight into the mechanisms that underlie this effect.

The studies will thus provide information on the mechanisms underlying defective axonal transport in ALS and may reveal new therapeutic targets for this disorder. Since disruption to axonal transport is seen in other neurodegenerative diseases, these results are likely to be informative about pathogenic processes in a number of these disorders.</gtr:technicalSummary><gtr:fund><gtr:end>2014-08-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-11-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1230988</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open day of MRC Centre for Neurodegeneration Research</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>274E5774-8B67-4F20-9196-212730A491AA</gtr:id><gtr:impact>Open day for public

I believe the impact was good -public found visit useful</gtr:impact><gtr:outcomeId>BA742500FEE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Institute of Psychiatry Neurodegeneration ARUK Open day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2405D468-A35C-4BA8-A18E-78C1D3A05543</gtr:id><gtr:impact>Over 100

The open days informed the public about the clinical aspects of Alzheimer's and dementia, and about ongoing research within King's on this topic. It involved presentations and visit to labs.</gtr:impact><gtr:outcomeId>rriYbimFQPE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://For 2013 https://www.kcl.ac.uk/iop/news/events/2013/april/Open-Day-Advert--IoP--donex.pdf</gtr:url><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>94051</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA PhD studentship2013</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>FE695AE4-06EC-4B30-B4E3-32777D998CC7</gtr:id><gtr:outcomeId>TmAjSjbH1Nc</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>159979</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's UK Project grant2014</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>DDF9C14D-7BD9-4563-BE81-2000D7956201</gtr:id><gtr:outcomeId>UDUjZFLfEV5</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>93838</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK PhD studentship2012</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>7FB4AFA1-1ADA-4707-BA01-9F39165ECC24</gtr:id><gtr:outcomeId>dLFjpKVJNih</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>367400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC ProjectGrant2014</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/L019299/1</gtr:fundingRef><gtr:id>20F87530-1F8A-4E40-A6F1-47411F179CB9</gtr:id><gtr:outcomeId>542d6c3929fdb3.45492049</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>461670</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK Project grant 2014</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>F90E951A-7F88-4AEB-81FB-C15C6404F66B</gtr:id><gtr:outcomeId>542d6b0985bc26.30074362</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7372440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CS -Wellcome Trust/MRC neurodegenerative diseases strategic award</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>9FE9B5E9-7483-45DA-A737-0EE6AF2414BB</gtr:id><gtr:outcomeId>1E95BD7F39A0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>261237</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK Project grant2012</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>5182C507-BDA7-472A-9F93-AA102E5B11CF</gtr:id><gtr:outcomeId>qRaJRPCxfE10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>165000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK equipment grant2013</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>8C59183D-3C76-452B-93E7-A9720452B5C5</gtr:id><gtr:outcomeId>LHViWvXV5QN</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>85004</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA PhD Studentship2010</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>37C0570A-DD4C-4400-951F-266133BAD002</gtr:id><gtr:outcomeId>D0BEC71C6670</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ARUK Scientific advisory board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C08958B5-C37C-4A7D-ACA7-FA4BF0FC676E</gtr:id><gtr:outcomeId>rPtfT88Hu15</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Antibodies to VAPB, PTPIP51 and phosphorylation dependent antibodies to LMTK2</gtr:description><gtr:id>919A7FF3-0F8A-4803-A712-B949C3EC8C7F</gtr:id><gtr:impact>We published work with these antibodies</gtr:impact><gtr:outcomeId>WuoocUrDRrb</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DNA clones and mutants of these for kinesin and kinesin light chain, neurofilaments, VAPB and PTPIP51.</gtr:description><gtr:id>0DD2610D-07BA-42F1-9893-2393FBCE4852</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>TWhCFkgbQpA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DNA clones</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EC8B8A68-F522-4D2A-9E3B-7E35605A5538</gtr:id><gtr:title>Cdk5/p35 phosphorylates lemur tyrosine kinase-2 to regulate protein phosphatase-1C phosphorylation and activity.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977dd99e12e9dd5668d74a35223fdb8e"><gtr:id>977dd99e12e9dd5668d74a35223fdb8e</gtr:id><gtr:otherNames>Manser C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>pm_13985_25_22220831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CD27D03-DF0A-46F1-B830-C4CA13D86AF8</gtr:id><gtr:title>Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93dc99c98b59b49150ea537d5c4c070a"><gtr:id>93dc99c98b59b49150ea537d5c4c070a</gtr:id><gtr:otherNames>Diekstra FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544bcf00f13c98.09263733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51D683CC-361C-4B8A-BEE9-FB282E1EDC48</gtr:id><gtr:title>Role of axonal transport in neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>Annual review of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d0493aca288feb1c7b928115cc28a"><gtr:id>a19d0493aca288feb1c7b928115cc28a</gtr:id><gtr:otherNames>De Vos KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0147-006X</gtr:issn><gtr:outcomeId>F516D23FAFA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B1766A5-015D-4EAA-9816-F13EE875C0A0</gtr:id><gtr:title>Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34ccfb591443e7db7227530de21d9b2a"><gtr:id>34ccfb591443e7db7227530de21d9b2a</gtr:id><gtr:otherNames>Rodr?guez-Mart?n T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>585d56d3091d62.71334211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F66B8C05-D059-4CE4-9CC9-6A880119DBB4</gtr:id><gtr:title>Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c831250c6d5af43302dbd12e99b4fb6"><gtr:id>1c831250c6d5af43302dbd12e99b4fb6</gtr:id><gtr:otherNames>Lee YB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_540e16ae16a8e0adb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5045F589-D26C-45FB-8245-A738E6E36942</gtr:id><gtr:title>Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a46cc13f73dd87b9293e1cd22958c7c"><gtr:id>6a46cc13f73dd87b9293e1cd22958c7c</gtr:id><gtr:otherNames>Stepto A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_540e16ae16a979aa1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31F0EABF-8966-47B0-96A1-1AF872DCF92E</gtr:id><gtr:title>Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaff144eb8c549f75ef3e66c1e865ad2"><gtr:id>aaff144eb8c549f75ef3e66c1e865ad2</gtr:id><gtr:otherNames>Mitchell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_13985_25_22961620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C241D91C-AC17-4B97-BE16-24416E082AD4</gtr:id><gtr:title>Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1db640afd979ca29b26d7ca6d657dfcf"><gtr:id>1db640afd979ca29b26d7ca6d657dfcf</gtr:id><gtr:otherNames>M?rotz GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13985_25_22258555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54E55C06-70E2-4742-AE47-B83A736815B2</gtr:id><gtr:title>Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5aa699e3687533.67844697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3807FC7-7AD4-4B03-B928-788D6F65DA1B</gtr:id><gtr:title>Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977dd99e12e9dd5668d74a35223fdb8e"><gtr:id>977dd99e12e9dd5668d74a35223fdb8e</gtr:id><gtr:otherNames>Manser C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>ogJLZ3D7GUs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E7E5428-83F4-4130-9E40-B26752E7C5E3</gtr:id><gtr:title>No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc23875dbdf591dfec98dd2283598bc3"><gtr:id>cc23875dbdf591dfec98dd2283598bc3</gtr:id><gtr:otherNames>Goris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544bcf0257e9b7.52663862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3646E82C-475A-4CCB-8052-E884FF50AD83</gtr:id><gtr:title>ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107e692c5cbfdd08a4bdfa319afca3cb"><gtr:id>107e692c5cbfdd08a4bdfa319afca3cb</gtr:id><gtr:otherNames>Vance C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13985_25_23474818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD91A7E4-88BD-422B-9010-C9AB9CD16B69</gtr:id><gtr:title>The four major N- and C-terminal splice variants of the excitatory amino acid transporter GLT-1 form cell surface homomeric and heteromeric assemblies.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a71d9227d6bdccb703b5d44801bf9da6"><gtr:id>a71d9227d6bdccb703b5d44801bf9da6</gtr:id><gtr:otherNames>Peacey E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>1EC6D2AACE3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CE0A1E3-EEB0-450B-9F62-BBA336728337</gtr:id><gtr:title>There's Something Wrong with my MAM; the ER-Mitochondria Axis and Neurodegenerative Diseases.</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07b27c4cc6acfceeef4bb9c47d3fe550"><gtr:id>07b27c4cc6acfceeef4bb9c47d3fe550</gtr:id><gtr:otherNames>Paillusson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>56dd82ebce0866.90793369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A004FBA2-2584-46EB-AA4B-D86A7698BA4B</gtr:id><gtr:title>Deficiency of the copper chaperone for superoxide dismutase increases amyloid-? production.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e2393c55b680a0a9751aada92841d9a"><gtr:id>8e2393c55b680a0a9751aada92841d9a</gtr:id><gtr:otherNames>Gray EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>MLATBSKucmM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F65BAF47-6C9B-4582-8D0C-C256382FD225</gtr:id><gtr:title>Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/514ce09c22d26da59e5c0c025e41fb21"><gtr:id>514ce09c22d26da59e5c0c025e41fb21</gtr:id><gtr:otherNames>Kasher PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>3AA25E75C64</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD857BB8-FA6B-40E1-816E-4603FD5DC00F</gtr:id><gtr:title>Autosomal dominant inheritance of rapidly progressive amyotrophic lateral sclerosis due to a truncation mutation in the fused in sarcoma (FUS) gene.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4764aa823b7a020b3590bce2cc799303"><gtr:id>4764aa823b7a020b3590bce2cc799303</gtr:id><gtr:otherNames>Kent L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>544bcf045a5fe5.17451079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>826A7480-5163-45C3-9796-27C5AC8F36C3</gtr:id><gtr:title>Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ecfd0497d0375c0a88359b331f4d279"><gtr:id>6ecfd0497d0375c0a88359b331f4d279</gtr:id><gtr:otherNames>Alami NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>544bcf031799a2.08217536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE4828B4-8A8D-4630-80BC-5B3E45750849</gtr:id><gtr:title>A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac5f45d8a5f9965eb360b3f6697fe0a9"><gtr:id>ac5f45d8a5f9965eb360b3f6697fe0a9</gtr:id><gtr:otherNames>Akimoto C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>544bcf03a36e01.94761814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A9AD820-C609-4B84-8ECA-22AD8D43AAF5</gtr:id><gtr:title>The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>544bcf013e1c05.46260780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5411795D-0EBF-4E6C-B65C-8A60DE83D785</gtr:id><gtr:title>Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d961018c784ae275e4710ba79802b77"><gtr:id>9d961018c784ae275e4710ba79802b77</gtr:id><gtr:otherNames>Tudor EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>cbu6SpzU4jW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D2CE504-6C39-4D87-9E2C-94D86D8BB1B2</gtr:id><gtr:title>Comment on &amp;quot;Drug screening for ALS using patient-specific induced pluripotent stem cells&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>544bcf01f119e7.52699369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A700B763-FBCF-48B3-B229-8CF8A4937EA3</gtr:id><gtr:title>The FE65 proteins and Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f188a79ab21dc7c1ceda56ac46be1108"><gtr:id>f188a79ab21dc7c1ceda56ac46be1108</gtr:id><gtr:otherNames>McLoughlin DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0360-4012</gtr:issn><gtr:outcomeId>634CBB26F8C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20F3A9E8-A3BB-4E00-992D-856CB23DD9C8</gtr:id><gtr:title>Disruption of ER-mitochondria signalling in fronto-temporal dementia and related amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15dba33c435f04f1407d468b87f8220d"><gtr:id>15dba33c435f04f1407d468b87f8220d</gtr:id><gtr:otherNames>Lau DHW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a9eac53d0c751.76017568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CA62376-A739-4B8B-A88D-07DDB34F1C46</gtr:id><gtr:title>A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa2841aab396cd2b4f18a94e7a29ae23"><gtr:id>aa2841aab396cd2b4f18a94e7a29ae23</gtr:id><gtr:otherNames>Morgan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5aa699e3d49b28.83252519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02695A7D-0A94-416E-A2D0-DC26658E7051</gtr:id><gtr:title>a-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Cahomeostasis and mitochondrial ATP production.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07b27c4cc6acfceeef4bb9c47d3fe550"><gtr:id>07b27c4cc6acfceeef4bb9c47d3fe550</gtr:id><gtr:otherNames>Paillusson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>5a254c7445ef21.45350174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>204F24A0-F070-445A-A275-5ADBD53EC46D</gtr:id><gtr:title>ALS/FTD-associated FUS activates GSK-3? to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77bcf36f991f182856eac148a0a0aa02"><gtr:id>77bcf36f991f182856eac148a0a0aa02</gtr:id><gtr:otherNames>Stoica R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>582de344524035.68663123</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>611C8D20-77A5-43EB-B094-7ACD06A23281</gtr:id><gtr:title>Phosphorylation of kinesin light chain 1 at serine 460 modulates binding and trafficking of calsyntenin-1.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d2958590e92e123756ca968495c9d76"><gtr:id>1d2958590e92e123756ca968495c9d76</gtr:id><gtr:otherNames>Vagnoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>jYz2rVYgYji</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>031F7D59-11C2-492C-B51C-9FF97964ED43</gtr:id><gtr:title>GULP1 is a novel APP-interacting protein that alters APP processing.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f6b1691ddb334c532ad5d4d823b01f"><gtr:id>f8f6b1691ddb334c532ad5d4d823b01f</gtr:id><gtr:otherNames>Hao Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>jm5FEezqtZq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC2F0487-FEC0-447F-A8C9-AB3F78EF0A45</gtr:id><gtr:title>Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c3f5a5bc7ae9744e72b93546e48cb6f"><gtr:id>7c3f5a5bc7ae9744e72b93546e48cb6f</gtr:id><gtr:otherNames>Ahmeti KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>544bcf016e38a3.28501419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48206EFB-8137-4E95-AA83-68CAFE93E702</gtr:id><gtr:title>Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9da89c318f56fc7256d9d74b60d23229"><gtr:id>9da89c318f56fc7256d9d74b60d23229</gtr:id><gtr:otherNames>Sims R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5aa699e46a4a55.51168519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D28E59F-14D8-4155-852F-49F9C37CF9B4</gtr:id><gtr:title>Transcriptional regulation of human FE65, a ligand of Alzheimer's disease amyloid precursor protein, by Sp1.</gtr:title><gtr:parentPublicationTitle>Journal of cellular biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32022d304cf2cada7c6b9ee1c6eb5e1a"><gtr:id>32022d304cf2cada7c6b9ee1c6eb5e1a</gtr:id><gtr:otherNames>Yu HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0730-2312</gtr:issn><gtr:outcomeId>jBvdMtUTZYQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD92D31-CF85-40B3-91F8-6ABA58F3117A</gtr:id><gtr:title>Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107e692c5cbfdd08a4bdfa319afca3cb"><gtr:id>107e692c5cbfdd08a4bdfa319afca3cb</gtr:id><gtr:otherNames>Vance C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>F494A89B3AC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08A5080C-D6B8-4FCF-95CE-70E563E80867</gtr:id><gtr:title>The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc7780d695b80ea4b2338692e2f37f70"><gtr:id>dc7780d695b80ea4b2338692e2f37f70</gtr:id><gtr:otherNames>Gomez-Suaga P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>58c155691418a6.83631728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6F646CA-69BE-46F0-AEF7-7E6279BD3DE0</gtr:id><gtr:title>A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ae0b5920edebc0579f77ebe7ddbb4e"><gtr:id>68ae0b5920edebc0579f77ebe7ddbb4e</gtr:id><gtr:otherNames>Fogh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544bcf02883315.60737102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08A09321-3167-43A6-A6A6-06DC9A194718</gtr:id><gtr:title>VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d0493aca288feb1c7b928115cc28a"><gtr:id>a19d0493aca288feb1c7b928115cc28a</gtr:id><gtr:otherNames>De Vos KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13985_25_22131369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>198D97F6-56D8-4D80-A02F-1CD227BF28F3</gtr:id><gtr:title>Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/648ce689029eb74519bb3610828d1173"><gtr:id>648ce689029eb74519bb3610828d1173</gtr:id><gtr:otherNames>van Eijk RPA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5aa699e5ebbea6.81534669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6790782D-810A-46AB-A7CD-E65685FCE18E</gtr:id><gtr:title>Deregulation of PKN1 activity disrupts neurofilament organisation and axonal transport.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977dd99e12e9dd5668d74a35223fdb8e"><gtr:id>977dd99e12e9dd5668d74a35223fdb8e</gtr:id><gtr:otherNames>Manser C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>20F07006D9E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDC7ABC2-0FA6-4311-A3C7-790492F2D179</gtr:id><gtr:title>Homozygosity analysis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb5ecebb0a95326732850cb51e132dc6"><gtr:id>bb5ecebb0a95326732850cb51e132dc6</gtr:id><gtr:otherNames>Mok K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>544bcf01c66b68.28467340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30A7D8E2-F36B-496A-94E5-DADD369E4D6C</gtr:id><gtr:title>X11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaff144eb8c549f75ef3e66c1e865ad2"><gtr:id>aaff144eb8c549f75ef3e66c1e865ad2</gtr:id><gtr:otherNames>Mitchell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5A436C07394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E5B492F-7C70-48CF-8E2F-962E8A59438A</gtr:id><gtr:title>Unpicking neurodegeneration in a dish with human pluripotent stem cells: one cell type at a time.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>544bcf0229e0f0.81404388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ED89FFB-D276-4FF5-B5A4-05EFE3E850B1</gtr:id><gtr:title>Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates A? production.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d2958590e92e123756ca968495c9d76"><gtr:id>1d2958590e92e123756ca968495c9d76</gtr:id><gtr:otherNames>Vagnoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13985_25_22434822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E664D47-A936-4912-9814-5ACC8A5E707C</gtr:id><gtr:title>Tar DNA-binding protein-43 (TDP-43) regulates axon growth in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0737bcb5a8ebef94755f6214dfe82972"><gtr:id>0737bcb5a8ebef94755f6214dfe82972</gtr:id><gtr:otherNames>Tripathi VB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>pm_540e16ae16aa32be5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB462D2D-5C03-4CC0-B566-D826EE4D1E09</gtr:id><gtr:title>Neurofilament subunit (NFL) head domain phosphorylation regulates axonal transport of neurofilaments.</gtr:title><gtr:parentPublicationTitle>European journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d797bc249bf8a8ae3b3b16815fc8a71f"><gtr:id>d797bc249bf8a8ae3b3b16815fc8a71f</gtr:id><gtr:otherNames>Yates DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0171-9335</gtr:issn><gtr:outcomeId>F40D17EABF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68C02EBF-2548-40AD-9EDE-CC8D6297B10B</gtr:id><gtr:title>The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aa73e328eb61ebd7307a45f0b5976b5"><gtr:id>9aa73e328eb61ebd7307a45f0b5976b5</gtr:id><gtr:otherNames>Martin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>5aa699e4e53521.11586011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>702EA2AC-022B-468F-B2C0-C8DE27E33DA8</gtr:id><gtr:title>RNA Misprocessing in-Linked Neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9adb0cf9c748d2062adf63457cc15ba4"><gtr:id>9adb0cf9c748d2062adf63457cc15ba4</gtr:id><gtr:otherNames>Barker HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>5aa699e5738790.24080771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B681FB19-D1E9-4463-B484-6A27F5755AD0</gtr:id><gtr:title>FE65 interacts with ADP-ribosylation factor 6 to promote neurite outgrowth.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61d6d45c777f3949f85a75b83d59a6f6"><gtr:id>61d6d45c777f3949f85a75b83d59a6f6</gtr:id><gtr:otherNames>Cheung HN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_13985_25_24056087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EAB50C3-5113-45C2-906A-2B022E686FBD</gtr:id><gtr:title>Riluzole protects against glutamate-induced slowing of neurofilament axonal transport.</gtr:title><gtr:parentPublicationTitle>Neuroscience letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58904c799610e27313785ab67f94117e"><gtr:id>58904c799610e27313785ab67f94117e</gtr:id><gtr:otherNames>Stevenson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0304-3940</gtr:issn><gtr:outcomeId>538CE2187A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20B71939-3F2B-4DC2-B057-F9FF5DBD75D5</gtr:id><gtr:title>ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77bcf36f991f182856eac148a0a0aa02"><gtr:id>77bcf36f991f182856eac148a0a0aa02</gtr:id><gtr:otherNames>Stoica R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>542d613c67b5d3.98304132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60BED34D-54BB-453A-AA76-E375AA7DDCDF</gtr:id><gtr:title>Dexras1 interacts with FE65 to regulate FE65-amyloid precursor protein-dependent transcription.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac7d64586c0ab5d56faf03fbd9903f"><gtr:id>74ac7d64586c0ab5d56faf03fbd9903f</gtr:id><gtr:otherNames>Lau KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>6858F015EFF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9D0CC9D-7BF6-4A40-8689-F5BC3CAE14A8</gtr:id><gtr:title>Neuromuscular disease: new insights and avenues for therapy.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>544bcf019cb4a7.27593700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56C5A98F-E241-49E0-8B53-05C3C7FC1FCE</gtr:id><gtr:title>Loss of c-Jun N-terminal kinase-interacting protein-1 does not affect axonal transport of the amyloid precursor protein or A? production.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d2958590e92e123756ca968495c9d76"><gtr:id>1d2958590e92e123756ca968495c9d76</gtr:id><gtr:otherNames>Vagnoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13985_25_23825109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DF9C84C-DA1C-4944-8A83-496EBEED4E7A</gtr:id><gtr:title>TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3e7348e74b192a401350c369dd08145"><gtr:id>d3e7348e74b192a401350c369dd08145</gtr:id><gtr:otherNames>Sreedharan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>3493DEE2ED8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3774C275-C7D7-4D35-B756-EC803403CDC9</gtr:id><gtr:title>Dissociation of Axonal Neurofilament Content from Its Transport Rate.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/adaf68c34a402d5e0c42de10cf0bd036"><gtr:id>adaf68c34a402d5e0c42de10cf0bd036</gtr:id><gtr:otherNames>Yuan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5645bf15c814a0.97686988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>242E032C-015C-4E4F-A7E8-D79A04660F6A</gtr:id><gtr:title>An X11alpha/FSBP complex represses transcription of the GSK3beta gene promoter.</gtr:title><gtr:parentPublicationTitle>Neuroreport</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac7d64586c0ab5d56faf03fbd9903f"><gtr:id>74ac7d64586c0ab5d56faf03fbd9903f</gtr:id><gtr:otherNames>Lau KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-4965</gtr:issn><gtr:outcomeId>HkaeAfgoLci</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>097207BC-75C6-4448-A0AF-7627B1520D92</gtr:id><gtr:title>Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>544bcf02dec130.64984146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>070580ED-406E-48DB-9850-878DD6F4B198</gtr:id><gtr:title>ATXN2 trinucleotide repeat length correlates with risk of ALS.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdc6e29ff1fbfb82d08db9aa811d9c11"><gtr:id>fdc6e29ff1fbfb82d08db9aa811d9c11</gtr:id><gtr:otherNames>Sproviero W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5aa699e29b59d1.36739737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C655C701-BF5B-47D1-B1E1-E6509067CC85</gtr:id><gtr:title>Expression of the neuronal adaptor protein X11alpha protects against memory dysfunction in a transgenic mouse model of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaff144eb8c549f75ef3e66c1e865ad2"><gtr:id>aaff144eb8c549f75ef3e66c1e865ad2</gtr:id><gtr:otherNames>Mitchell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>E1iUP7Gsiqq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AF3C6B3-06AC-40A0-BF7A-D439933A800E</gtr:id><gtr:title>ER-mitochondria signaling regulates autophagy.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc7780d695b80ea4b2338692e2f37f70"><gtr:id>dc7780d695b80ea4b2338692e2f37f70</gtr:id><gtr:otherNames>Gomez-Suaga P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>5a254bee7017d6.22227201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDA42066-6B55-4763-A657-C7E1A7FE7110</gtr:id><gtr:title>Myosin VI and its interacting protein LMTK2 regulate tubule formation and transport to the endocytic recycling compartment.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7033e97d1828ab385aeadc8e2460eb7"><gtr:id>b7033e97d1828ab385aeadc8e2460eb7</gtr:id><gtr:otherNames>Chibalina MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>7682445E8F1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>947CE6CF-DBF7-49B9-B5D2-DCFABC940BAC</gtr:id><gtr:title>Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c71e4a1411fff60038bd9e6b563c927"><gtr:id>8c71e4a1411fff60038bd9e6b563c927</gtr:id><gtr:otherNames>Godena VK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5444ebafcd9e58.24041591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>876C45C6-8F4D-4661-855A-CC5952AD1230</gtr:id><gtr:title>Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d0493aca288feb1c7b928115cc28a"><gtr:id>a19d0493aca288feb1c7b928115cc28a</gtr:id><gtr:otherNames>De Vos KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>BBCDA301BDC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>514FBD69-29D1-4EEC-9084-2AB1084CAE4F</gtr:id><gtr:title>An evaluation of a SVA retrotransposon in the FUS promoter as a transcriptional regulator and its association to ALS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3108c31a0519408ba70fe51961bbba10"><gtr:id>3108c31a0519408ba70fe51961bbba10</gtr:id><gtr:otherNames>Savage AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544bcf03736d30.04611140</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501573</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>